

GGGAGGACTTGAAAGAGCCACCACATTTTCACCGAGGCCACGGGAGTACGATCGAGTGTACAGTGAACAATGCTAGGGAGAGCTGCCTATATGGAAGAGCCCTAATGTGTAAAATTAATTTTAGTAGTGCTATCCCATGTGATTTTAATAGCTTCTTAGGAGA
ATGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Variant table of passage 3 (#100998, lot 26102020)

In green are variants present in the sequence provided by the depositor.

Details about the sequencing protocol is available on request.

Position (NC_045512.2)	Ref	Alt	SNP/indel	Syn/NonSyn	Proportion	Gene
241	C	T	SNP	N/A	0.9994	CHR_START-ORF1ab
3037	C	T	SNP	Syn	0.9988	ORF1ab
9502	C	T	SNP	Syn	0.0118	ORF1ab
12085	C	T	SNP	Syn	0.0135	ORF1ab
14408	C	T	SNP	Pro-->Leu	0.9996	ORF1ab
21552	C	T	SNP	Syn	0.0197	ORF1ab
23403	A	G	SNP	Asp-->Gly	0.9997	S
24388	A	T	SNP	Syn	0.9998	S
24990	C	T	SNP	Pro-->Leu	0.0486	S
26258	T	C	SNP	Val-->Ala	0.9654	E

APPLICATIONS

Infectivity assay, viral growth, neutralisation assay.

DEPOSITOR

Original virus (passage 2) received from Prof Arvind Patel, The MRC-University of Glasgow Centre for Virus Research, The University of Glasgow. Passage 3 virus grown by CFAR.

REFERENCE

Rihn et al., (2020). Manuscript in preparation

ACKNOWLEDGMENTS

Acknowledgment for publications should read "The following reagent was obtained from the Centre For AIDS Reagents, NIBSC, UK: SARS-CoV-2 infectious virus (CVR-GLA 1)".

